Bridgebio Pharma

Forecast & Rating22 analysts currently cover Bridgebio Pharma, with about 86.4% giving a positive rating — meaning they expect the stock to rise. The average price target is $109.10, about 62.2% upside from the current price of $67.25. Price targets range from $80.00 to $157.00 — a wide spread, showing clear disagreement over just how much Bridgebio Pharma can rise. Historically, about 64.8% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Bridgebio Pharma closely still see room for the stock to rise. Data as of Oct 1, 2026; for reference only and not investment advice.